3349.T
COSMOS Pharmaceutical Corporation
プライム · 小売業 · 小売 · JP
JPY 6,672.00
+4.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1042.6B | 1011.4B | 965.0B | 827.7B | 755.4B |
| Cost of Revenue | 215.2B | 798.1B | 776.7B | 659.0B | 604.0B |
| Gross Profit | 57.2B | 213.3B | 188.3B | 168.7B | 151.4B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 45.5B | 172.9B | 156.8B | 138.6B | 121.7B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 45.5B | 172.9B | 156.8B | 138.6B | 121.7B |
| Cost and Expenses | 1001.9B | 971.0B | 933.5B | 797.6B | 725.6B |
| Operating Income (EBIT) | 40.7B | 40.4B | 31.5B | 30.1B | 29.8B |
| Non-Operating | |||||
| Interest Income | 27.0M | 48.0M | 44.0M | 47.0M | 52.0M |
| Interest Expense | 110.0M | 254.0M | 99.0M | 51.0M | 52.0M |
| Net Interest Income | (83.0M) | (206.0M) | (55.0M) | (4.0M) | — |
| Other Non-Op Income/Expense | 544.0M | 2.8B | 2.8B | 3.0B | 3.1B |
| Non-Operating Income (excl Interest) | 769.0M | 3.7B | 3.6B | 3.6B | 3.6B |
| EBT (Pre-Tax Income) | 12.1B | 42.4B | 33.7B | 32.8B | 33.0B |
| Income Tax Expense | 3.9B | 11.4B | 9.3B | 9.0B | 9.9B |
| Bottom Line | |||||
| Net Income | 31.2B | 31.0B | 24.5B | 23.8B | 23.2B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 31.2B | 31.0B | 24.5B | 23.8B | 23.2B |
| Per Share | |||||
| Basic EPS | ¥394 | ¥391 | ¥617 | ¥601 | ¥585 |
| Diluted EPS | ¥394 | — | — | — | — |
| Revenue Per Share | ¥13,155 | ¥12,761 | ¥24,356 | ¥20,902 | ¥19,077 |
| Shares | |||||
| Basic Shares Outstanding | 79.3M | 79.3M | 39.6M | 39.6M | 39.6M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 62.6B | 51.4B | 47.5B | 44.9B |
| D&A | — | 22.2B | 19.9B | 17.4B | 15.1B |
| EBIT | 40.7B | 40.4B | 31.5B | 30.1B | 29.8B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Feb 1, 2026